This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Thymoglobulin

Sanofi

Drug Names(s): anti-thymocyte globulin, antithymocyte globulin, rATG

Description: Thymoglobulin is made up of a variety of antibodies that recognize key receptors on T-cells, the cells responsible for organ transplant rejection. Thymoglobulin is believed to inactivate and kill these T-cells, thus neutralizing the rejection process and allowing the transplanted organ to recover.

Deal Structure: Historical drug revenue includes Thymoglobulin and Lymphoglobuline. Sanofi stopped reporting Thymoglobulin revenue, therefore revenues after 2010 are BioMedTracker estimates.

In 2003, Genzyme acquired Thymoglobulin through the acquisition of Sangstate Medical Corporation.

In June 2010, Genzyme and Hospira entered into an agreement for Hospira to perform fill and finish manufacturing services for Genzyme's products, including Cerezyme, Fabrazyme, Myozyme, Lumizyme, Thyrogen, Thymoglobulin, Campath and certain of Genzyme's product candidates in development.

In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.


Thymoglobulin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug